NCT00282932

Detrol LA In Men With Overactive Bladder.

A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 600 (planned)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: Male
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and other secondary endpoints like bladder diary endpoints, quality of life and patient treatment satisfaction. Patients included in the study must have symptoms of OAB (frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary). Patients are not eligible to enroll in the study if they have/had significant hepatic or renal disease, history of radiation treatment.

Conditions

• Overactive Bladder (OAB)

Interventions

Type	Name	Description
DRUG	Detrol LA

Timeline

• Start date: 2006-01-01
• Primary completion: 2007-05-01
• Completion: 2007-05-14
• First posted: 2006-01-27
• Last updated: 2021-01-27

Locations

81 sites across 15 countries: United States, Canada, Denmark, Germany, Italy, Mexico, Norway, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom